Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer

Executive Summary

ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.

Advertisement

Related Content

Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
Is ICER Too NICE? A Comparison Of Drug Assessments Programs
Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
ICER Review Of NSCLC Drugs To Include Roche’s Pending Indication For Tecentriq
ICER Questions Cost Effectiveness Of Empliciti, Kyprolis, Ninlaro

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel